The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지

Overview of RCT for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis

  • Son, Chang-Gue (Liver and Immunology Research Center of Oriental Medicine College, Daejeon University)
  • Received : 2011.05.03
  • Accepted : 2011.05.11
  • Published : 2011.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: This study aimed to get information on the current status of therapies to date for non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH). Methods: All randomized clinical controlled trial (RCT)-derived papers for NAFLD or NASH were reviewed via PubMed Database. Results: 39 RCTs met the review criteria, of which 15 and 24 papers were for NAFLD and NASH, respectively. 83% of the papers were released since 2006, and 30 studies were conducted for western medicines, antioxidants and lifestyle intervention whereas nine trials were done using herbal medicine or acupuncture which showed positive outcome. Conclusions: NAFLD and NASH are new epidemic disorders which can be a target of traditional Oriental medicine. This study will be helpful for the Oriental medicine-based strategies or therapeutic development for them.

Keywords

References

  1. Chavez-Tapia NC, Rosso N, Tiribelli C. In Vitro Models for the Study of Non-Alcoholic Fatty Liver Disease. Current Medicinal Chemistry, 2011; 18(7):1079-84. https://doi.org/10.2174/092986711794940842
  2. Adams LA, Angulo P. Treatment of nonalcoholic fatty liver disease. Postgrad Med J. 2006; 82 (967):315-22. https://doi.org/10.1136/pgmj.2005.042200
  3. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA, 2003; 289 (22): 3000-4. https://doi.org/10.1001/jama.289.22.3000
  4. Farrell GC, Chitturi S, Lau GK, Sollano JD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007; 22(6):775-7. https://doi.org/10.1111/j.1440-1746.2007.05002.x
  5. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol. 2010 Apr; 25(4):672-90. https://doi.org/10.1111/j.1440-1746.2010.06253.x
  6. Omagari K, Kadokawa Y, Masuda J, Egawa I, Sawa T, Hazama H, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol. 2002; 17(10):1098-105. https://doi.org/10.1046/j.1440-1746.2002.02846.x
  7. Tsuruta G, Tanaka N, Hongo M, Komatsu M, Horiuchi A, Hamamoto K, et al. Nonalcoholic fatty liver disease in Japanese junior high school students: its prevalence and relationship to lifestyle habits. J Gastroenterol. 2010; 45(6):666-72. https://doi.org/10.1007/s00535-009-0198-4
  8. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005; 43(3):508-14. https://doi.org/10.1016/j.jhep.2005.02.042
  9. Zhou YJ, Li YY, Nie YQ, Ma JX, Lu LG, Shi SL, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol. 2007; 13(47):6419-24. https://doi.org/10.3748/wjg.13.6419
  10. Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol. 2006; 40(8):745-52. https://doi.org/10.1097/00004836-200609000-00016
  11. J Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2006; 21(1 Pt 1):138-43. https://doi.org/10.1111/j.1440-1746.2005.04086.x
  12. Neuschwander-Tetri BA. Lifestyle modification as the primary treatment of NASH. Clin Liver Dis. 2009; 13(4):649-65. https://doi.org/10.1016/j.cld.2009.07.006
  13. Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Del Vecchio Blanco C, et al. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut. 2006; 55(6): 901-2. https://doi.org/10.1136/gut.2006.091967
  14. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology. 2010; 51(2):445-53. https://doi.org/10.1002/hep.23270
  15. Miglio F, Rovati LC, Santoro A, Setnikar I. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung. 2000; 50(8):722-7.
  16. Haukeland JW, Konopski Z, Eggesbo HB, von Volkmann HL, Raschpichler G, Bjoro K, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol. 2009; 44(7):853-60. https://doi.org/10.1080/00365520902845268
  17. Nobili V, Manco M, Devito R, Ciampalini P, Piemonte F, Marcellini M. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006; 24(11-12):1553-61. https://doi.org/10.1111/j.1365-2036.2006.03161.x
  18. Li L, Zhang XJ, Lan Y, Xu L, Zhang XZ, Wang HH. Treatment of non-alcoholic fatty liver disease by Qianggan Capsule. Chin J Integr Med. 2010; 16(1):23-7. https://doi.org/10.1007/s11655-010-0023-1
  19. Lou SY, Liu Y, Ma YY, Chen HY, Chen WH, Ying J, et al. Effects of Yiqi Sanju Formula on non-alcoholic fatty liver disease: a randomized controlled trial Zhong Xi Yi Jie He Xue Bao. 2008; 6(8):793-8. https://doi.org/10.3736/jcim20080805
  20. Ji G, Fan JG, Chen JJ, Lu LG, Xing LJ, Zheng PY, et al. Effectiveness of Danning Tablet in patients with non-alcoholic fatty liver of dampheat syndrome type: a multicenter randomized controlled trial. Zhong Xi Yi Jie He Xue Bao. 2008; 6(2):128-33. https://doi.org/10.3736/jcim20080205
  21. Gu CL, Zhang YK, Fu YX, Yang SF, Li XQ. Effect of tiaozhi yanggan decoction in treating patients with non-alcoholic fatty liver. Chin J Integr Med. 2007; 13(4):275-9. https://doi.org/10.1007/s11655-007-0275-6
  22. Ji G, Fan JG, Chen JJ. Clinical study on treatment of non-alcoholic fatty liver of damp-heat syndrome type by danning tablet. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005; 25(6):485-8.
  23. Chande N, Laidlaw M, Adams P, Marotta P. Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): a randomized pilot study. Dig Dis Sci. 2006; 51 (7):1183-9. https://doi.org/10.1007/s10620-006-8030-y
  24. Zhang SJ, Chen ZX, Jiang KP, Cheng YH, Gu YL. The effect of QuYuHuaTanTongLuo Decoction on the non-alcoholic steatohepatitis. Complement Ther Med. 2008; 16(4):192-8. https://doi.org/10.1016/j.ctim.2007.08.004
  25. Wang YL. Yiqi Huoxue Recipe combined with polyene phosphatidycholine capsule in treating 50 patients with non-alcoholic fatty hepatitis. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007; 27(2):162-4.
  26. Meng SX. Observation on therapeutic effect of acupuncture for treatment of patients with nonalcoholic steatohepatitis. Zhongguo Zhen Jiu. 2009; 29(8):616-8.
  27. Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis. 2007; 11(1):105-17. https://doi.org/10.1016/j.cld.2007.02.013
  28. Elias MC, Parise ER, de Carvalho L, Szejnfeld D, Netto JP. Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease. Nutrition. 2010; 26(11-12):1094-9. https://doi.org/10.1016/j.nut.2009.09.001
  29. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010; 51(1):121-9. https://doi.org/10.1002/hep.23276
  30. Nadeau KJ, Ehlers LB, Zeitler PS, Love-Osborne K. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes. 2009; 10(1):5-13. https://doi.org/10.1111/j.1399-5448.2008.00450.x
  31. Videla LA, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med. 2006; 12(12):555-8. https://doi.org/10.1016/j.molmed.2006.10.001
  32. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003; 98 (11):2485-90. https://doi.org/10.1111/j.1572-0241.2003.08699.x
  33. Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ, Zeuzem S, Hein J, Berg T. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2010; 52(2):472-9. https://doi.org/10.1002/hep.23727
  34. Balmer ML, Siegrist K, Zimmermann A, Dufour JF. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int. 2009; 29(8):1184-8. https://doi.org/10.1111/j.1478-3231.2009.02037.x
  35. Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, et al. Randomized placebocontrolled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2006; 4(12):1537-43. https://doi.org/10.1016/j.cgh.2006.09.025
  36. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004; 39(3):770-8. https://doi.org/10.1002/hep.20092
  37. Chavez-Tapia NN, Uribe M, Ponciano- Rodríguez G, Medina-Santillán R, Méndez- Sánchez N. New insights into the pathophysiology of nonalcoholic fatty liver disease. Ann Hepatol. 2009; 8:S9-S17.
  38. Han CW, Lee JH. Effects of KHchunggan-tang on the Nonalcoholic Fatty Liver Disease in Palmitate-induced Cellular Model. J Korean Oriental Med 2011; 32(1):109-20.
  39. Yoo JY, Lee JH. Effect of Saengangtanggamibang on nonalcoholic fatty liver disease model induced by fatty liver. Korean J. Orient. Int. 2007; Spring(1):143-57.
  40. Yun KS, Woo HJ, Lee JH, Kim YC. Effect of Injinchunggan-tang and Injinsaryung-san on NASH induced by MCD-diet In A/J mice. Orient. Int. 2009; 30(2):410-21.